The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Tumor penetrating peptides for improved drug delivery
Open accessAbstract
Abstract In vivo screening of phage libraries in tumor‐bearing mice has been used to identify peptides that direct phage homing to a tumor. The power of in vivo phage screening is illustrated by the recent discovery of peptides with unique tumor‐penetrating properties. These peptides activate an endocytic transport pathway related to but distinct from macropinocytosis. They do so through a complex process that involves binding to a primary, tumor‐specific receptor, followed by a proteolytic cleavage, and binding to a second receptor. The second receptor, neuropilin‐1 (or neuropilin‐2) activates the transport pathway. This trans‐tissue pathway, dubbed the C‐end Rule (CendR) pathway, mediates the extravasation transport through extravascular tumor tissue of payloads ranging from small molecule drugs to nanoparticles. The CendR technology provides a solution to a major problem in tumor therapy, poor penetration of drugs into tumors. Targeted delivery with tumor‐penetrating peptides has been shown to specifically increase the accumulation of drugs, antibodies and nanotherapeutics in experimental tumors in vivo, and in human tumors ex vivo. Remarkably the payload does not have to be coupled to the peptide; the peptide activates a bulk transport system that sweeps along a drug present in the blood. Treatment studies in mice have shown improved anti‐tumor efficacy and less damage to normal tissues with drugs ranging from traditional chemotherapeutics to antibodies, and to nanoparticle drugs. Graphical abstract Figure. No Caption available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pierschbacher, M. D., & Ruoslahti, E. (1984) · Nature · doi:10.1038/309030a0 · Cited by 3,658
Self-citationHigh Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Tian, Y., Li, S., Song, J., Ji, T., Zhu, M., Anderson, G. J., Wei, J., & Nie, G. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.083 · Cited by 1,801
Organ targeting In vivo using phage display peptide libraries
Pasqualini, R., & Ruoslahti, E. (1996) · Nature · doi:10.1038/380364a0 · Cited by 1,221
Self-citationTissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Girard, O. M., Hanahan, D., Mattrey, R. F., & Ruoslahti, E. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.013 · Cited by 1,136
Self-citationCoadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., & Ruoslahti, E. (2010) · Science · doi:10.1126/science.1183057 · Cited by 1,075
Self-citationIntercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein
Elliott, G., & O'Hare, P. (1997) · Cell · doi:10.1016/s0092-8674(00)81843-7 · Cited by 972
Cell-specific targeting of nanoparticles by multivalent attachment of small molecules
Weissleder, R., Kelly, K., Sun, E. Y., Shtatland, T., & Josephson, L. (2005) · Nature Biotechnology · doi:10.1038/nbt1159 · Cited by 904
Enhanced Permeability and Retention (EPR) Effect for Anticancer Nanomedicine Drug Targeting
Greish, K. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-609-2_3 · Cited by 841
Targeting of drugs and nanoparticles to tumors
Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200910104 · Cited by 829
Self-citationTumor imaging by means of proteolytic activation of cell-penetrating peptides
Jiang, T., Olson, E. S., Nguyen, Q. T., Roy, M., Jennings, P. A., & Tsien, R. Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408191101 · Cited by 822
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
Teesalu, T., Sugahara, K. N., Kotamraju, V. R., & Ruoslahti, E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908201106 · Cited by 812
Self-citationTrojan peptides: the penetratin system for intracellular delivery
Derossi, D., Chassaing, G., & Prochiantz, A. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)80017-2 · Cited by 722
Jain, R. K., & Baxter, L. T. (1988) · PubMed · Cited by 714
Cationic TAT peptide transduction domain enters cells by macropinocytosis
Kaplan, I. M., Wadia, J. S., & Dowdy, S. F. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.10.018 · Cited by 668
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors
Primeau, A. J., Rendon, A., Hedley, D., Lilge, L., & Tannock, I. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1664 · Cited by 499
A tumor-homing peptide with a targeting specificity related to lymphatic vessels
Laakkonen, P., Porkka, K., Hoffman, J. A., & Ruoslahti, E. (2002) · Nature Medicine · doi:10.1038/nm720 · Cited by 498
Self-citationNucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels
Christian, S., Pilch, J., Akerman, M. E., Porkka, K., Laakkonen, P., & Ruoslahti, E. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200304132 · Cited by 497
Self-citationPeptides as Targeting Elements and Tissue Penetration Devices for Nanoparticles
Ruoslahti, E. (2012) · Advanced Materials · doi:10.1002/adma.201200454 · Cited by 419
Self-citationTAT transduction: the molecular mechanism and therapeutic prospects
Gump, J. M., & Dowdy, S. F. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.002 · Cited by 356
Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma
Agemy, L., Friedmann-Morvinski, D., Kotamraju, V. R., Roth, L., Sugahara, K. N., Girard, O. M., Mattrey, R. F., Verma, I. M., & Ruoslahti, E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114518108 · Cited by 347
Self-citationMitochondrial/Cell-Surface Protein p32/gC1qR as a Molecular Target in Tumor Cells and Tumor Stroma
Fogal, V., Zhang, L., Krajewski, S., & Ruoslahti, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6752 · Cited by 346
Self-citationFogal, V., Richardson, A. D., Karmali, P. P., Scheffler, I. E., Smith, J. W., & Ruoslahti, E. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01101-09 · Cited by 329
Self-citationv Integrins in Angiogenesis and Cancer
Weis, S. M., & Cheresh, D. A. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006478 · Cited by 311
Porkka, K., Laakkonen, P., Hoffman, J. A., Bernasconi, M., & Ruoslahti, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062189599 · Cited by 291
Self-citationAntitumor activity of a homing peptide that targets tumor lymphatics and tumor cells
Laakkonen, P., Åkerman, M. E., Biliran, H., Yang, M., Ferrer, F., Karpanen, T., Hoffman, R. M., & Ruoslahti, E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403317101 · Cited by 275
Self-citationExogenous siRNA delivery using peptide transduction domains/cell penetrating peptides
Meade, B. R., & Dowdy, S. F. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.004 · Cited by 274
Yan, F., Wu, H., Liu, H., Deng, Z., Liu, H., Duan, W., Liu, X., & Zheng, H. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.050 · Cited by 254
Protein transduction domain delivery of therapeutic macromolecules
van den Berg, A., & Dowdy, S. F. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.03.008 · Cited by 247
In Vivo Targeting of Hydrogen Peroxide by Activatable Cell-Penetrating Peptides
Weinstain, R., Savariar, E. N., Felsen, C. N., & Tsien, R. Y. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411547j · Cited by 239
Transtumoral targeting enabled by a novel neuropilin-binding peptide
Roth, L., Agemy, L., Kotamraju, V. R., Braun, G., Teesalu, T., Sugahara, K. N., Hamzah, J., & Ruoslahti, E. (2012) · Oncogene · doi:10.1038/onc.2011.537 · Cited by 231
Self-citationTherapeutic Nanoparticles to Combat Cancer Drug Resistance
Hu, C.-M., & Zhang, L. (2009) · Current Drug Metabolism · doi:10.2174/138920009790274540 · Cited by 223
Wang, X., Zhen, X., Wang, J., Zhang, J., Wu, W., & Jiang, X. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.008 · Cited by 218
Joyce, J. A., Laakkonen, P., Bernasconi, M., Bergers, G., Ruoslahti, E., & Hanahan, D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00271-x · Cited by 211
Self-citationAn endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability
Pang, H.-B., Braun, G. B., Friman, T., Aza-Blanc, P., Ruidiaz, M. E., Sugahara, K. N., Teesalu, T., & Ruoslahti, E. (2014) · Nature Communications · doi:10.1038/ncomms5904 · Cited by 195
Self-citationLigand-targeted theranostic nanomedicines against cancer
Yao, V. J., D'Angelo, S., Butler, K. S., Theron, C., Smith, T. L., Marchiò, S., Gelovani, J. G., Sidman, R. L., Dobroff, A. S., Brinker, C. J., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.002 · Cited by 195
Hu, Q., Gu, G., Liu, Z., Jiang, M., Kang, T., Miao, D., Tu, Y., Pang, Z., Song, Q., Yao, L., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.048 · Cited by 194
Thayanithy, V., Dickson, E. L., Steer, C., Subramanian, S., & Lou, E. (2014) · Translational Research · doi:10.1016/j.trsl.2014.05.011 · Cited by 182
De Novo Design of a Tumor-Penetrating Peptide
Alberici, L., Roth, L., Sugahara, K. N., Agemy, L., Kotamraju, V. R., Teesalu, T., Bordignon, C., Traversari, C., Rizzardi, G.-P., & Ruoslahti, E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1668 · Cited by 175
Self-citationYagi, M., Uchiumi, T., Takazaki, S., Okuno, B., Nomura, M., Yoshida, S.-I., Kanki, T., & Kang, D. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks774 · Cited by 169
Kumar, A., Huo, S., Zhang, X., Liu, J., Tan, A., Li, S., Jin, S., Xue, X., Zhao, Y., Ji, T., et al. (2014) · ACS Nano · doi:10.1021/nn500152u · Cited by 162
Multifunctional porous silicon nanoparticles for cancer theranostics
Wang, C.-F., Sarparanta, M. P., Mäkilä, E. M., Hyvönen, M. L. K., Laakkonen, P. M., Salonen, J. J., Hirvonen, J. T., Airaksinen, A. J., & Santos, H. A. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.01.008 · Cited by 160
Chaudhary, A., Hilton, M. B., Seaman, S., Haines, D. C., Stevenson, S., Lemotte, P. K., Tschantz, W. R., Zhang, X. M., Saha, S., Fleming, T., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.004 · Cited by 159
Bagri, A., Tessier‐Lavigne, M., & Watts, R. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0563 · Cited by 154
Gu, G., Gao, X., Hu, Q., Kang, T., Liu, Z., Jiang, M., Miao, D., Song, Q., Yao, L., Tu, Y., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.036 · Cited by 138
Design of a Tumor-Homing Cell-Penetrating Peptide
Myrberg, H., Zhang, L., Mäe, M. A., & Langel, Ü. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0701139 · Cited by 137
Tumor-Penetrating iRGD Peptide Inhibits Metastasis
Sugahara, K. N., Braun, G. B., de Mendoza, T. H., Kotamraju, V. R., French, R. P., Lowy, A. M., Teesalu, T., & Ruoslahti, E. I. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0366 · Cited by 137
Self-citationBy-passing of P-glycoprotein Using Immunoliposomes
Huwyler, J., Cerletti, A., Fricker, G., Eberlé, A. N., & Drewe, J. (2002) · Journal of drug targeting · doi:10.1080/10611860290007559 · Cited by 125
Zhu, Z., Xie, C., Liu, Q., Xu, Z. C., Zheng, X., Wu, W., Li, R., Ding, Y., Jiang, X., & Liu, B. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.08.072 · Cited by 118
Hamzah, J., Kotamraju, V. R., Seo, J. W., Agemy, L., Fogal, V., Mahakian, L. M., Peters, D., Roth, L., Gagnon, M.-H., Ferrara, K. W., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104540108 · Cited by 117
Self-citationHenke, E., Perk, J., Vider, J., de Candia, P., Chin, Y., Solit, D. B., Ponomarev, V., Cartegni, L., Manova, K., Rosen, N. X., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1366 · Cited by 117
Uchida, M., Kosuge, H., Terashima, M., Willits, D. A., Liepold, L. O., Young, M., McConnell, M. V., & Douglas, T. (2011) · ACS Nano · doi:10.1021/nn102863y · Cited by 116
Targeting neuropilin-1 in human leukemia and lymphoma
Karjalainen, K., Jaalouk, D. E., Bueso-Ramos, C., Zurita, A. J., Kuniyasu, A., Eckhardt, B. L., Marini, F. C., Lichtiger, B., O'Brien, S. M., Kantarjian, H. M., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282921 · Cited by 113
Mapping of Vascular ZIP Codes by Phage Display
Teesalu, T., Sugahara, K. N., & Ruoslahti, E. I. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-396962-0.00002-1 · Cited by 112
Self-citationCun, X., Chen, J., Ruan, S., Zhang, L., Wan, J., He, Q., & Gao, H. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b09391 · Cited by 109
Sha, H., Zou, Z., Xin, K., Bian, X., Cai, X., Lu, W., Chen, J., Chen, G., Huang, L., Blair, A. M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.039 · Cited by 104
Li, M., Tang, Z., Zhang, D., Sun, H. Y., Liu, H., Zhang, Y., Zhang, Y., & Chen, X. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.002 · Cited by 100
Hamilton, A. M., Aidoudi-Ahmed, S., Sharma, S., Kotamraju, V. R., Foster, P. J., Sugahara, K. N., Ruoslahti, E. I., & Rutt, B. K. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1279-x · Cited by 98
Self-citationSong, W., Li, M., Tang, Z., Li, Q., Yang, Y., Liu, H., Duan, T., Hong, H., & Chen, X. (2012) · Macromolecular Bioscience · doi:10.1002/mabi.201200145 · Cited by 96
New p32/gC1qR Ligands for Targeted Tumor Drug Delivery
Paasonen, L., Sharma, S., Braun, G. B., Kotamraju, V. R., Chung, T. D. Y., She, Z., Sugahara, K. N., Yliperttula, M. L., Wu, B., Pellecchia, M., et al. (2016) · ChemBioChem · doi:10.1002/cbic.201500564 · Cited by 93
Self-citationAkashi, Y., Oda, T., Ohara, Y., Miyamoto, R., Kurokawa, T., Hashimoto, S., Enomoto, T., Yamada, K., Satake, M., & Ohkohchi, N. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.49 · Cited by 90
Connor, Y., Tekleab, S., Nandakumar, S., Walls, C., Tekleab, Y., Husain, A., Gadish, O., Sabbisetti, V. S., Kaushik, S., Sehrawat, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9671 · Cited by 88
Miao, D., Jiang, M., Liu, Z., Gu, G., Hu, Q., Kang, T., Song, Q., Yao, L., Li, W., Gao, X., et al. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400189j · Cited by 85
Pang, H., Braun, G. B., & Ruoslahti, E. I. (2015) · Science Advances · doi:10.1126/sciadv.1500821 · Cited by 84
Self-citationNanomedicines Targeting the Tumor Microenvironment
Tong, R., & Langer, R. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000123 · Cited by 79
Lymphatic Zip Codes in Premalignant Lesions and Tumors
Zhang, L., Giraudo, E., Hoffman, J. A., Hanahan, D., & Ruoslahti, E. I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3876 · Cited by 77
Self-citationMolecular Changes in the Vasculature of Injured Tissues
Järvinen, T. A. H., & Ruoslahti, E. I. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061251 · Cited by 74
Self-citationA tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis
Sugahara, K. N., Scodeller, P., Braun, G. B., de Mendoza, T. H., Yamazaki, C. M., Kluger, M. D., Kitayama, J., Alvarez, E. A., Howell, S. B., Teesalu, T., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.009 · Cited by 72
Self-citationPuig-Saus, C., Rojas, L. A., Laborda, E., Figueras, A., Alba, R., Fillat, C., & Alemany, R. (2014) · Gene Therapy · doi:10.1038/gt.2014.52 · Cited by 71
Shen, J., Meng, Q., Sui, H., Yin, Q., Zhang, Z., Yu, H., & Li, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400576f · Cited by 70
Shin, T. H., Sung, E.-S., Kim, Y., Kim, S.-H., Kim, S.-K., Kim, S.-K., Lee, Y., & Kim, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0748 · Cited by 68
Zhang, X., Yu, Zhang, W.-Q., Luo, L.-M., Song, P., Li, D., Du, Ren, Huang, Lü, W.-L., et al. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s46962 · Cited by 66
Yan, Z., Zhan, C., Wen, Z., et al. (2011) · Nanotechnology · doi:10.1088/0957-4484/22/41/415103 · Cited by 64
Ni, D., Ding, H., Liu, S., Yue, H., Bao, Y., Wang, Z., Su, Z. G., Wei, W., & Ma, G. (2015) · Small · doi:10.1002/smll.201403632 · Cited by 63
Schmithals, C., Köberle, V., Korkusuz, H., Pleli, T., Kakoschky, B., Augusto, E. A., Ibrahim, A. A., Arencibia, J. M., Vafaizadeh, V., Groner, B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0395 · Cited by 62
Enhanced Therapeutic Efficacy of iRGD-Conjugated Crosslinked Multilayer Liposomes for Drug Delivery
Liu, Y., Ji, M. K., Wong, M. K. K., Joo, K., & Wang, P. (2013) · BioMed Research International · doi:10.1155/2013/378380 · Cited by 62
Mao, X.-L., Liu, J., Gong, Z., Zhang, H., Lü, Y., Zou, H. L., Yu, Y., Chen, Y., Sun, Z., Li, W., et al. (2015) · Nanomedicine · doi:10.2217/nnm.15.106 · Cited by 61
Application of a Proapoptotic Peptide to Intratumorally Spreading Cancer Therapy
Chen, R., Braun, G. B., Luo, X., Sugahara, K. N., Teesalu, T., & Ruoslahti, E. I. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1979 · Cited by 58
Self-citationDai, W., Fan, Y., Zhang, H., Wang, X., Zhang, Q., & Wang, X. (2014) · Drug Delivery · doi:10.3109/10717544.2014.903580 · Cited by 46
Quantity and accessibility for specific targeting of receptors in tumours
Hussain, S., Rodriguez-Fernández, M., Braun, G. B., Doyle, F. J., & Ruoslahti, E. I. (2014) · Scientific Reports · doi:10.1038/srep05232 · Cited by 40
Self-citationZhang, Q., Zhang, Y., Li, K., Wang, H., Li, H., & Zheng, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129865 · Cited by 38
Zhang, X., Du, R., Zhong, T., Zhang, W.-Q., Song, P., Song, W.-D., Zhao, Y., Wang, C., Tang, Y., & Zhang, Q. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s65664 · Cited by 36
A Tumor-Penetrating Peptide Modification Enhances the Antitumor Activity of Thymosin Alpha 1
Lao, X., Liu, M., Chen, J., & Zheng, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072242 · Cited by 35
Furin Targeted Drug Delivery for Treatment of Rhabdomyosarcoma in a Mouse Model
Hajdin, K., D’Alessandro, V., Niggli, F. K., Schäfer, B. W., & Bernasconi, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010445 · Cited by 35
Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment
De, G., Ko, J., Tan, T., Zhu, H., Li, H., & Ma, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2301 · Cited by 32
Ren, T., Liu, S., Li, G., et al. (2012) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2012.06.005 · Cited by 19
Kandela, I. K., Chou, J., Chow, K., & Reproducibility Project: Cancer Biology (2015) · eLife · doi:10.7554/elife.06959 · Cited by 8
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
Engineered nanomedicines with enhanced tumor penetration
Ding, J., Chen, J., Gao, L., Jiang, Z., Zhang, Y., Li, M., Xiao, Q., Lee, S. S., & Chen, X. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100800 · Cited by 420
Bridging Bio–Nano Science and Cancer Nanomedicine
Björnmalm, M., Thurecht, K. J., Michael, M., Scott, A. M., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04855 · Cited by 382
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Controlling the biodistribution and clearance of nanomedicines
Cabral, H., Li, J., Miyata, K., & Kataoka, K. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00138-1 · Cited by 303
Metadata
- Authors
- Ruoslahti, E.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 110-111
- Pages
- 3-12
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2319963189
- Cited by
- 459
- References
- 87
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.